Privacy

Cookie Policy

Contact

Home

ABOUT

Editorial

PRESS RELEASES

MEDICAL DEVICE NEWS MAGAZINE

A DIGITAL PUBLICATION FOR THE PRACTICING MEDICAL SPECIALIST, INDUSTRY EXECUTIVE AND INVESTOR

SUBSCRIBE

Market Reports

FDA

Executives

Funding

Non Profits

Hospitals

Acquisitions

Health

Biotechnology News Magazine

Todor Jeliaskov Appointed CEO of inHEART

inHEART, the leader in image guidance for treatment of cardiac arrhythmias, has appointed Todor Jeliaskov as CEO. He will lead the French company in its mission to bridge the gap between cardiology and medical imaging with a digital twin of the patient’s heart. Todor Jeliaskov will work closely with co-founder and former CEO Jean-Marc Peyrat, who transitions to the role of CTO at inHEART.

“I am thrilled to welcome Todor as our new CEO,” said Jean-Marc Peyrat, co-founder of inHEART. “His proven leadership and experience perfectly complement our existing team to scale up the company and to support its ambition to be a major player in the double-digit growing market of cardiac electrophysiology.”

Todor Jeliaskov brings over 20 years of experience solving customers’ needs and generating returns for investors and shareholders at large, complex enterprises and startup organizations across continents and various industries. Before inHEART, Todor Jeliaskov was CEO of NuVera Medical, acquired by Biosense Webster (Johnson & Johnson) in November 2020. NuVera developed the next-generation of ultrasound imaging technology for cardiac interventions – 4D ICE. Todor Jeliaskov previously served as VP at GE Ultrasound, the worldwide market leader in diagnostic ultrasound. Todor Jeliaskov started his career at Siemens Medical Solutions. He holds a Ph.D. in Electrical Engineering and an MBA degree.

“I am honored to join the exceptionally talented inHEART team that developed a unique solution for the guidance of cardiac ablations. It is rare to see new technologies with such a substantial impact on patient care.” said Todor Jeliaskov. “I am excited to be part of this revolution and I look forward to driving its international deployment to make it accessible to most patients.”

“At Elaia, we congratulate Todor Jeliaskov on his selection as Chief Executive Officer, we’re excited by the tremendous progress inHEART has made since Elaia’s investment in 2020 under Jean-Marc Peyrat’s leadership as CEO and would like to thank him and welcome him as the new Chief Technology Officer of the company,” said Samantha Jérusalmy, Partner at Elaia. “We are confident that inHEART is poised for strong growth and Todor’s commercial leadership and management experience are unique assets in this new phase.” explains Sacha Loiseau, Venture Partner at Elaia.

Other News

HypnoVR Raises €4.5 Million

The funds will allow HypnoVR to accelerate the commercial roll-out of its virtual reality-based medical hypnosis solution in France and globally. The company will also be stepping up efforts in its award-winning R&D program in order to further increase the therapeutic efficacy of its solution and broaden its scope of application to other medical and paramedical fields. 

Fluidx Medical Technology Announces Series A Led by Multinational Strategic Investor

Fluidx Medical Technology, a privately held medical device company founded to develop GPX, an innovative embolic material, and other technologies today announced the oversubscribed...

Trajan Group Acquires Axel Semrau GmbH

Trajan's automation business and Axel Semrau have worked in close cooperation for several years.

Alpheus Medical Closes $16M In Series A Financing For Novel Glioma Brain Cancer Treatment

Funds to support first-in-human (FIH) clinical trial of the company's proprietary, non-invasive sonodynamic drug-device therapy system for recurrent high-grade gliomas.
spot_img

By using this website you agree to accept Medical Device News Magazine Privacy Policy